Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Investments (2016 - 2025)

United Therapeutics' Long-Term Investments history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 20.43% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 20.43%, while the annual FY2025 figure was $1.8 billion, 20.43% up from the prior year.
  • Long-Term Investments for Q4 2025 was $1.8 billion at United Therapeutics, up from $1.6 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $2.1 billion in Q3 2023 and bottomed at $1.3 billion in Q3 2024.
  • The 5-year median for Long-Term Investments is $1.6 billion (2022), against an average of $1.6 billion.
  • The largest annual shift saw Long-Term Investments skyrocketed 65.15% in 2021 before it crashed 37.92% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $1.6 billion in 2021, then fell by 20.23% to $1.3 billion in 2022, then surged by 45.1% to $1.9 billion in 2023, then decreased by 22.75% to $1.5 billion in 2024, then rose by 20.43% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Long-Term Investments are $1.8 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.9 billion (Q2 2025).